Publikationen in Zusammenarbeit mit Forschern von Universidad del País Vasco/Euskal Herriko Unibertsitatea (26)

2019

  1. BFL1 modulates apoptosis at the membrane level through a bifunctional and multimodal mechanism showing key differences with BCLXL

    Cell Death and Differentiation, Vol. 26, Núm. 10, pp. 1880-1894

2018

  1. The 2-oxoglutarate carrier promotes liver cancer by sustaining mitochondrial GSH despite cholesterol loading

    Redox Biology, Vol. 14, pp. 164-177

2015

  1. Minimalist model systems reveal similarities and differences between membrane interaction modes of MCL1 and BAK

    Journal of Biological Chemistry, Vol. 290, Núm. 27, pp. 17004-17019

2014

  1. Apaf-1 inhibitors protect from unwanted cell death in In vivo models of kidney ischemia and chemotherapy induced ototoxicity

    PLoS ONE, Vol. 9, Núm. 10

  2. Lipid-dependent bimodal mcl1 membrane activity

    ACS Chemical Biology, Vol. 9, Núm. 12, pp. 2852-2863

2013

  1. Proapoptotic Bax and Bak proteins form stable protein-permeable pores of tunable size

    Journal of Biological Chemistry, Vol. 288, Núm. 46, pp. 33241-33252

2011

  1. Reconstitution of proapoptotic BAK function in liposomes reveals a dual role for mitochondrial lipids in the BAK-driven membrane permeabilization process

    Journal of Biological Chemistry, Vol. 286, Núm. 10, pp. 8213-8230

2010

  1. Cholesterol and peroxidized cardiolipin in mitochondrial membrane properties, permeabilization and cell death

    Biochimica et Biophysica Acta - Bioenergetics, Vol. 1797, Núm. 6-7, pp. 1217-1224

  2. Liposome-bound APO2L/TRAIL is an effective treatment in a rabbit model of rheumatoid arthritis

    Arthritis and Rheumatism, Vol. 62, Núm. 8, pp. 2272-2282

2008

  1. BIM and tBID are not mechanistically equivalent when assisting BAX to permeabilize bilayer membranes

    Journal of Biological Chemistry, Vol. 283, Núm. 12, pp. 7790-7803

  2. Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma

    Cancer Research, Vol. 68, Núm. 13, pp. 5246-5256

2006

  1. Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody

    FEBS Letters, Vol. 580, Núm. 9, pp. 2395-2399

2005

  1. Asymmetric addition of ceramides but not dihydroceramides promotes transbilayer (flip-flop) lipid motion in membranes

    Biophysical Journal, Vol. 88, Núm. 1, pp. 348-359

2002

  1. Membrane fusion: The process and its energy suppliers

    Cellular and Molecular Life Sciences, Vol. 59, Núm. 9, pp. 1478-1490

2000

  1. Sphingolipids (galactosylceramide and sulfatide) in lamellar-hexagonal phospholipid phase transitions and in membrane fusion

    Langmuir, Vol. 16, Núm. 23, pp. 8958-8963

1999

  1. Interbilayer lipid mixing induced by the human immunodeficiency virus type-1 fusion peptide on large unilamellar vesicles: The nature of the nonlamellar intermediates

    Chemistry and Physics of Lipids, Vol. 103, Núm. 1-2, pp. 11-20

  2. Interfacial enzyme activation, non-lamellar phase formation and membrane fusion. Is there a conducting thread?

    Faraday Discussions, Vol. 111, pp. 55-68

1998

  1. Effect of single chain lipids on phospholipase C-promoted vesicle fusion. A test for the stalk hypothesis of membrane fusion

    Biochemistry, Vol. 37, Núm. 11, pp. 3901-3908

1997

  1. Morphological changes induced by phospholipase C and by sphingomyelinase on large unilamellar vesicles: A cryo-transmission electron microscopy study of liposome fusion

    Biophysical Journal, Vol. 72, Núm. 6, pp. 2630-2637

  2. Poly(ethylene glycol)-lipid conjugates inhibit phospholipase C-induced lipid hydrolysis, liposome aggregation and fusion through independent mechanisms

    FEBS Letters, Vol. 411, Núm. 2-3, pp. 281-286